

Supplementary

Table S1 Comparison of clinicopathological characteristics between 5 different BMI group in luminal A patients

Variables	Total (n=49)	<18.5 (n=6)	18.5–23.9 (n=26)	24–26.9 (n=10)	27–29.9 (n=5)	≥30 (n=2)	P value
Age (years)							
<50	30	6	17	7	0	0	0.002
≥50	19	0	9	3	5	2	
Tumor size							
≤2 cm	14	2	7	4	0	1	0.632
2–5 cm	33	4	18	5	5	1	
>5 cm	2	0	1	1	0	0	
Lymph nodes status							
–	25	2	15	5	2	1	0.833
+	24	4	11	5	3	1	

BMI, body mass index.

Table S2 Comparison of clinicopathological characteristics between 5 different BMI group in Luminal B patients

Variables	Total (n=171)	<18.5 (n=10)	18.5–23.9 (n=110)	24–26.9 (n=32)	27–29.9 (n=14)	≥30 (n=5)	P value
Age (years)							
<50	113	5	83	16	7	2	0.010
≥50	58	5	27	16	7	3	
Tumor size							
≤2 cm	31	2	19	8	2	0	0.566
2–5 cm	127	6	82	22	12	5	
>5 cm	13	2	9	2	0	0	
Lymph nodes status							
–	75	4	46	16	7	2	0.916
+	96	6	64	16	7	3	

BMI, body mass index.

Table S3 Comparison of clinicopathological characteristics between 5 different BMI group in HER2 patients

Variables	Total (n=51)	<18.5 (n=2)	18.5–23.9 (n=33)	24–26.9 (n=13)	27–29.9 (n=2)	≥30 (n=1)	P value
Age (years)							
<50	25	0	19	6	0	0	0.193
≥50	26	2	14	7	2	1	
Tumor size							
≤2 cm	6	0	5	1	0	0	0.337
2–5 cm	36	2	20	12	1	1	
>5 cm	9	0	8	0	1	0	
Lymph nodes status							
–	25	1	19	5	0	0	0.406
+	26	1	14	8	2	1	

BMI, body mass index; HER2, human epidermal growth factor receptor-2.

Table S4 Comparison of clinicopathological characteristics between 5 different BMI group in TNBC patients

Variables	Total (n=44)	<18.5 (n=1)	18.5–23.9 (n=24)	24–26.9 (n=13)	27–29.9 (n=5)	≥30 (n=1)	P value
Age (years)							
<50	28	1	17	6	4	0	0.286
≥50	16	0	7	7	1	1	
Tumor size							
≤2 cm	8	1	3	3	0	1	0.240
2–5 cm	31	0	18	9	4	0	
>5 cm	5	0	3	1	1	0	
Lymph nodes status							
–	22	1	13	7	1	0	0.454
+	22	0	11	6	4	1	

BMI, body mass index; TNBC, triple negative breast cancer.